Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

Pain

Volumn 111, Issue 3, 2004, Pages 306-312

  Body, Jean Jacques ^a   Diel, Ingo J ^b   Bell, Richard ^c   Pecherstorfer, Martin ^d   Lichinitser, Michail R ^e   Lazarev, Alexander F ^f   Tripathy, Debu ^g   Bergström, Bengt ^h  

^a JULES BORDET INSTITUTE   (Belgium)

^b CGG Klinik GmbH   (Germany)

^c Vic Australia   (Australia)

^d WILHELMINEN HOSPITAL   (Austria)

^e Cancer Research Center   (Russian Federation)

^f Oncological Center   (Russian Federation)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

Author keywords

Bisphosphonate; Breast cancer; Co analgesic; Ibandronate; Metastatic bone pain; Quality of life

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PLACEBO;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUODENUM BLEEDING; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PAIN; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC;

EID: 4444337297     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2004.07.011     Document Type: Article

References (44)

1. N.K. Aaronson, S. Ahmedzai, B. Bergman, N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N.J. Duez, A. Filiberti, H. Flechtner, S.B. Fleishman, and J.C. de Haes The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
2. Agency for Health Care Policy and Research Management of cancer pain: clinical practice guidelines AHCPR publication 94-0592 1994 US Department of Health and Human Services Rockville, MD
3. A.R. Belch, D.E. Bergsagel, K. Wilson, S. O'Reilly, J. Wilson, D. Sutton, J. Pater, D. Johnston, and B. Zee Effect of daily etidronate on the osteolysis of multiple myeloma J Clin Oncol 9 1991 1397 1402
4. R. Bell, D. Tripathy, J.J. Body, M. Pecherstorfer, I. Diel, and B. Bergstrom Oral ibandronate: an effective, convenient and well-tolerated therapy for metastatic bone disease Support Care Cancer 11 2003 415 (Abstract A-105)
5. J.R. Berenson, A. Lichtenstein, L. Porter, M.A. Dimopoulos, R. Bordoni, S. George, A. Lipton, A. Keller, O. Ballester, M.J. Kovacs, H.A. Blacklock, R. Bell, J. Simeone, D.J. Reitsma, M. Heffernan, J. Seaman, and R.D. Knight Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma N Engl J Med 334 1996 488 493
6. J.J. Body Bisphosphonates for metastatic bone pain Support Care Cancer 7 1999 1 3
7. J.J. Body, R. Bartl, P. Burckhardt, P.D. Delmas, I.J. Diel, H. Fleisch, J.A. Kanis, R.A. Kyle, G.R. Mundy, A.H. Paterson, and R.D. Rubens Current use of bisphosphonates in oncology. International Bone and Cancer Study Group J Clin Oncol 16 1998 3890 3899
8. J.J. Body, J. Kanis, I. Diel, and B. Bergstrom Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate Proc ASCO 22 2003 46 (Abstract 184)
9. J.J. Body, I.J. Diel, M.R. Lichinitser, E.D. Kreuser, W. Dornoff, V.A. Gorbunova, M. Budde, B. Bergström, and the MF 4265 study group Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
10. J.J. Body, I.J. Diel, M. Lichinitser, A. Lazarev, M. Pecherstorfer, R. Bell, D. Tripathy, and B. Bergström Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
11. J.J. Bonica Management of cancer pain Acta Anaesthesiol Scand 74 1982 75 82
12. J.T. Chang, L. Green, and J. Beitz Renal failure with the use of zoledronic acid N Engl J Med 349 2003 1676 1679
13. R.E. Coleman Assessment of response to treatment R.D. Rubens I. Forgelman Bone metastases: diagnosis and treatment 1991 Springer Berlin 99 120
14. R.E. Coleman, P.J. Woll, M. Miles, W. Scrivener, and R.D. Rubens Treatment of bone metastases from breast cancer with (3-amino-1- hydroxypropylidene)-1,1-bisphosphonate (APD) Br J Cancer 58 1988 621 625
15. P.F. Conte, J. Latreille, L. Mauriac, F. Calabresi, R. Santos, D. Campos, J. Bonneterre, G. Francini, and J.M. Ford Delay in progression of bone metastases in breast cancer patients treated with i.v. pamidronate: results from a multinational randomised controlled trial J Clin Oncol 14 1996 2552 2559
16. J. Costanino The impact of hormonal treatments on quality of life in patients with metastatic breast cancer Clin Ther 24 2002 C26 C42
17. I.J. Diel, J.J. Body, D. Tripathy, and B. Bergstrom Oral daily ibandronate in women with metastatic breast cancer: a pooled safety analysis Proc ASCO 22 2003 47 (Abstract 186)
18. I. Elomaa, T. Kylmala, T. Tammela, J. Viitanen, J. Ottelin, M. Ruutu, K. Jauhiainen, M. Ala-Opas, L. Roos, and J. Seppanen Effect of oral clodronate on bone pain - a controlled study in patients with metastatic prostate cancer Int Urol Nephrol 24 1992 159 166
19. D.S. Ernst, R.N. MacDonald, A.H. Paterson, J. Jensen, P. Brasher, and E. Bruera A double-blind, crossover trial of intravenous clodronate in metastatic bone pain J Pain Symptom Manage 7 1992 4 11
20. D.S. Ernst, P. Brasher, N. Hagen, A.H. Paterson, R.N. MacDonald, and E. Bruera Controlled trial of intravenous clodronate in patients with metastatic bone disease and pain Proc Am Soc Clin Oncol 1 1994 431 (Abstract 1478)
21. F. Fulfaro, A. Casuccio, C. Ticozzi, and C. Ripamonti The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials Pain 78 1998 157 169
22. G.N. Hortobagyi, R.L. Theriault, L. Porter, D. Blayney, A. Lipton, C. Sinoff, H. Wheeler, J.F. Simeone, J. Seaman, and R.D. Knight Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases N Engl J Med 335 1996 1785 1791
23. G.N. Hortobagyi, R.L. Theriault, A. Lipton, L. Porter, D. Blayney, C. Sinoff, H. Wheeler, J.F. Simeone, J.J. Seaman, R.D. Knight, M. Heffernan, K. Mellars, and D.J. Reitsma Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate J Clin Oncol 16 1998 2038 2044
24. S.P. Jagdev, O.P. Purohit, S. Heatley, C. Herlin, and R.E. Coleman Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease Ann Oncol 12 2001 1433 1438
25. N. Janjan Bone metastases: approaches to management Semin Oncol 28 2001 28 34
26. B. Kristensen, B. Ejlertsen, M. Groenvold, S. Hein, H. Loft, and H.T. Mouridsen Oral clodronate in breast cancer patients with bone metastases: a randomized study J Intern Med 246 1999 67 74
27. R. Lahtinen, M. Lansko, I. Palva, P. Virkkunen, and I. Elomaa Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma Lancet 340 1992 1049 1052
28. M.E. Lippman, A.S. Lichter, and D.N. Danford Diagnosis and management of breast cancer 1998 WB Saunders Philadelphia, PA p. 569-574
29. A. Lipton, R.L. Theriault, G.N. Hortobagyi, J. Simeone, R.D. Knight, K. Mellars, D.J. Reitsma, M. Heffernan, and J.J. Seaman Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials Cancer 88 2000 1082 1090
30. I. Mancini, J.C. Duman, C. Toth, and J.J. Body Short-term treatment with the bisphosphonate ibandronate for opioid resistant metastatic bone pain Bone 30 Suppl 3 2002 51 (Abstract B56)
31. S. Marsoni, S. Hurson, and M. Eisenberger Chemotherapy of bone metastases S. Garranttini Bone resorption, metastases and diphosphonates 1985 Raven Press New York, NY 181 195
32. S. Mercadante Malignant bone pain: pathophysiology and treatment Pain 69 1997 1 18
33. C. Ohlmann, and A. Heidenreich Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer Support Care Cancer 11 2003 396 (Abstract A-38)
34. N. O'Rourke, E. McCloskey, F. Houghton, H. Huss, and J.A. Kanis Double-blind, placebo-controlled, dose-response trial or oral clodronate in patients with bone metastases J Clin Oncol 13 1995 929 934
35. N. Pavlakis, and M. Stockler Bisphosphonates for breast cancer Cochrane Database Syst Rev 1 2002 CD003474
36. L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J.A. Mackey, J. Apffelstaedt, M. Hussein, R.E. Coleman, D.J. Reitsma, J.J. Seaman, B.L. Chen, and Y. Ambros Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 2001 377 387
37. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, B. Chen, and Zoledronic Acid Prostate Cancer Study Group A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
38. A.N. Serafini Therapy of metastatic bone pain J Nucl Med 42 2001 895 906
39. E.J. Small, M.R. Smith, J.J. Seaman, S. Petrone, and M.O. Kowalski Combined analysis of two multicenter randomizd, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastastic prostate cancer J Clin Oncol 21 2003 4277 4284
40. J.A. Smith Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, double-blind, placebo-controlled study J Urol 141 1989 85 87
41. M. Stockler, N.R. Wilcken, D. Ghersi, and R.J. Simes Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer Cancer Treat Rev 26 2000 151 168
42. R.L. Theriault, A. Lipton, G.N. Hortobagyi, R. Leff, S. Gluck, J.F. Stewart, S. Costello, I. Kennedy, J. Simeone, J.J. Seaman, R.D. Knight, K. Mellars, M. Heffernan, and D.J. Reitsma Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial J Clin Oncol 17 1999 846 854
43. D. Tripathy, M. Pecherstorfer, R. Bartl, R. Bell, I. Diel, and B. Bergstrom Reduction in risk of skeletal events with ibandronate in the treatment of metastatic breast cancer Support Care Cancer 11 2003 427 (Abstract A-152)
44. World Health Organization Cancer pain relief and palliative care: report of a WHO expert committee 1990 World Health Organization Geneva, Switzerland